Please login to the form below

Not currently logged in
Email:
Password:

Yervoy

This page shows the latest Yervoy news and features for those working in and with pharma, biotech and healthcare.

BMS CEO tackles investor ‘frustrations’ on immuno-oncology

BMS CEO tackles investor ‘frustrations’ on immuno-oncology

and it’s being trying to recover with trials of Opdivo and Yervoy in combination. ... With comparison to the data that we saw at ESMO, we continue to believe that Opdivo plus Yervoy has a very competitive profile, ”said Boerner.

Latest news

  • Merck’s Bavencio joins first-line kidney cancer face-off Merck’s Bavencio joins first-line kidney cancer face-off

    Both combinations could challenge the position of Bristol-Myers Squibb’s Opdivo (nivolumab) and Yervoy (ipilimumab), which has started to replace Sutent and other TKIs like Exelixis’Cabometyx (cabozantinib) as the ... However, it’s notable that

  • Keytruda hits survival targets in first-line kidney cancer Keytruda hits survival targets in first-line kidney cancer

    Bristol-Myers Squibb’s cancer immunotherapy pairing of PD-1 inhibitor Opdivo (nivolumab) and CTLA4 inhibitor Yervoy (ipilimumab) was approved earlier this year as first-line treatment for RCC, but only ... BMS is hoping to extend Opdivo’s use in first

  • BMS finds a new immunotherapy partner with $12m Compugen deal BMS finds a new immunotherapy partner with $12m Compugen deal

    In February, it signed a huge $3.6bn deal to pair Nektar's NKTR-214 with Opdivo and its CTLA4 inhibitor Yervoy (ipilimumab) in a host of tumour types.

  • Checkpoint inhibitor scientists win Nobel Prize Checkpoint inhibitor scientists win Nobel Prize

    at the heart of research into CTLA4 which led to the development of inhibitors such as BMS’ Yervoy (ipilimumab) and various late-stage clinical candidates. ... Two years later the antibody – now called Yervoy – was approved by the FDA for melanoma

  • NICE turns down Opdivo for adjuvant melanoma therapy NICE turns down Opdivo for adjuvant melanoma therapy

    Opdivo was approved for adjuvant treatment of melanoma on the back of data from the CheckMate-238 trial showing that it was superior to BMS’CTLA4 inhibitor Yervoy (ipilimumab) in reducing ... There was a 35% reduction in the risk of recurrence or death

More from news
Approximately 31 fully matching, plus 136 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics